Citadel Advisors’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.22M | Buy |
528,993
+312,382
| +144% | +$722K | ﹤0.01% | 3118 |
|
|
2025
Q1 | $301K | Sell |
216,611
-528,594
| -71% | -$735K | ﹤0.01% | 4469 |
|
|
2024
Q4 | $1.29M | Sell |
745,205
-2,114,767
| -74% | -$3.66M | ﹤0.01% | 3036 |
|
|
2024
Q3 | $5.75M | Buy |
2,859,972
+2,813,118
| +6,004% | +$5.65M | ﹤0.01% | 1659 |
|
|
2024
Q2 | $105K | Buy |
46,854
+46,657
| +23,684% | +$105K | ﹤0.01% | 4932 |
|
|
2024
Q1 | $566 | Sell |
197
-2,297,359
| -100% | -$6.6M | ﹤0.01% | 5965 |
|
|
2023
Q4 | $4.07M | Buy |
+2,297,556
| New | +$4.07M | ﹤0.01% | 1791 |
|
|
2023
Q3 | – | Sell |
-11,293
| Closed | -$7.47K | – | 6514 |
|
|
2023
Q2 | $7.47K | Hold |
11,293
| – | – | ﹤0.01% | 5413 |
|
|
2023
Q1 | $9.01K | Sell |
11,293
-172,418
| -94% | -$138K | ﹤0.01% | 5536 |
|
|
2022
Q4 | $415K | Buy |
183,711
+133,131
| +263% | +$301K | ﹤0.01% | 4033 |
|
|
2022
Q3 | $97K | Sell |
50,580
-60,011
| -54% | -$115K | ﹤0.01% | 5130 |
|
|
2022
Q2 | $411K | Sell |
110,591
-98,158
| -47% | -$365K | ﹤0.01% | 4336 |
|
|
2022
Q1 | $1.36M | Buy |
208,749
+172,412
| +474% | +$1.12M | ﹤0.01% | 3414 |
|
|
2021
Q4 | $423K | Buy |
+36,337
| New | +$423K | ﹤0.01% | 4761 |
|
|
2021
Q1 | – | Sell |
-35,752
| Closed | -$949K | – | 6814 |
|
|
2020
Q4 | $949K | Sell |
35,752
-209,282
| -85% | -$5.56M | ﹤0.01% | 3296 |
|
|
2020
Q3 | $5.49M | Buy |
+245,034
| New | +$5.49M | ﹤0.01% | 1443 |
|